Enhanced SN-38 Formulations with Poly(amino acid) Block Copolymers

This inventive concept relates to improved formulations of SN-38 with poly(amino acid) block copolymers, enhancing solubility, stability, and efficacy in cancer treatment.

The original patent disclosed formulations of SN-38 with poly(amino acid) copolymers, but limitations existed in terms of solubility, stability, and specificity. The new inventive concept addresses these limitations by introducing modifications to the copolymer, such as hydrophilic moieties, specific molecular weights, and targeting moieties, to create more effective and targeted cancer treatments.

The new inventive concept comprises four key aspects: (1) a system for delivering SN-38 with a poly(amino acid) block copolymer modified with a hydrophilic moiety to enhance aqueous solubility; (2) a method for treating cancer using a formulation with a poly(amino acid) block copolymer engineered to have a specific molecular weight and polydispersity to optimize its pharmacokinetic profile; (3) a pharmaceutical composition with a poly(amino acid) block copolymer functionalized with a targeting moiety to enhance specificity and efficacy; and (4) a process for preparing a SN-38 formulation with improved stability using a sugar-based excipient as a stabilizing agent. These innovations enable the creation of more effective and targeted cancer treatments.

The new inventive concept introduces novel modifications to the poly(amino acid) block copolymer, such as hydrophilic moieties and targeting moieties, which are not disclosed in the original patent. These modifications provide a significant improvement in solubility, stability, and specificity, making the new inventive concept non-obvious and novel compared to the original patent.

Alternative embodiments of the inventive concept could include using different types of hydrophilic moieties, varying the molecular weight and polydispersity of the copolymer, or incorporating additional functional groups to enhance targeting and efficacy. These variations would ensure broad conceptual coverage and adaptability to different applications.

The enhanced SN-38 formulations with poly(amino acid) block copolymers have significant commercial potential in the cancer treatment market, particularly in the development of targeted and efficacious therapies. The market for cancer treatments is substantial, and the new inventive concept has the potential to capture a significant share of this market.